A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects
The PD-1/PD-L1 axis is a major pathway involved in tumor immune evasion. Here, we report the novel PD-L1 antagonizing DNA aptamer (aptPD-L1) and demonstrate an integrated pipeline that expedites therapeutic aptamer development. Aptamer can exert antibody-mimic functions and is advantageous over anti...
Main Authors: | Wei-Yun Lai, Bo-Tsang Huang, Jen-Wei Wang, Pei-Ying Lin, Pan-Chyr Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253117300185 |
Similar Items
-
Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
by: Aaron Prodeus, et al.
Published: (2015-01-01) -
Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects
by: Xie S, et al.
Published: (2021-08-01) -
Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01) -
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
by: Christie P. M. Verkleij, et al.
Published: (2020-12-01) -
PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab
by: Gabriele Madonna, et al.
Published: (2018-12-01)